The size of the Asia-Pacific Therapeutic Vaccines Market was estimated at USD 734.73 Million in 2021. It is forecasted to worth USD 3690.61 Million by 2026, growing at a CAGR of 38.1% between 2021 to 2026.
Therapeutic vaccines are biologicals that are intended to treat a viral infection by stimulating the immune system. The therapeutic vaccine Market is different from any other product market. Compared to the pharmaceutical market, it is relatively small, although growing at a fast rate. In the pipeline, several approaches are being developed to boost the immune response to various infectious and cancerous cells. There are presently close to 120 new vaccines in the pipeline of various multinational companies across the globe set to hit the market in the next few years.
Coming to the Asian Market, Yisheng Biopharma, in China, has developed a new vaccine for the post-exposure treatment of rabies infection and is set to enter human clinical trials after a six-year collaboration with research institutes worldwide. In India, Bharat Biotech claimed to have achieved a breakthrough in developing a vaccine to fight the deadly Zika virus, which causes serious congenital disabilities in children.
An increase in funding’s from the government for vaccine development, a rise in investments by the major market players, rising prevalence of the disease, technological advancements, initiatives by NGOs are some of the factors that are propelling the market growth. However, massive capital expenditures, stringent regulatory policies, and high costs associated with treatment are few factors inhibiting its growth.
This research report on the APAC Therapeutic Vaccines Market segmented and sub-segmented into the following categories:
By Disease Type:
By Country:
Major companies operating in the Asia Pacific Therapeutic Vaccines Market covered in this report are GlaxoSmithKline, plc, Merck and Company, Bavarian Nordic, CSL Limited, Emergent BioSolutions Inc., Novartis AG, Johnson and Johnson, MedImmune, LLC, Pfizer, Inc., and Sanofi Pasteur.
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2.1 Introduction
2.2 Analysis Design
2.3 Research Phases
2.3.1 Secondary Research
2.3.2 Primary Research
2.3.3 Econometric Modelling
2.3.4 Expert Validation
2.4 Study Timeline
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5.1 By Disease Type
5.1.1 Autoimmune Disease Vaccines
5.1.2 Cancer Vaccines
5.1.2.1 Multikine
5.1.2.2 PR1 Peptide
5.1.2.3 TroVax
5.1.2.4 CYT004-MelQbG10
5.1.3 Neurological Disease Vaccines
5.1.3.1 ACC- 001
5.1.3.2 CAD 106
5.1.3.3 Parkinson's Disease Vaccine
5.1.3.4 Alzheimer's Disease
5.1.4 Infectious Disease Vaccines
5.1.4.1 Hepatitis C
5.1.4.2 HIV/AIDS
5.1.4.3 Other Infectious Disease
6.1 Introduction
6.2 China
6.3 India
6.4 Japan
6.5 South Korea
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.1 GlaxoSMithKline plc.
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Strategic Evaluation and Operations
8.1.4 Financial analysis
8.1.5 Legal issues
8.1.6 Recent Developments
8.1.7 SWOT analysis
8.1.8 Analyst View
8.2 Merck and Company
8.3 Bavarian Nordic
8.4 CSL Limited
8.5 Emergent Biosolutions Inc.
8.6 Novartis AG
8.7 Johnson and Johnson
8.8 MedImmune LLC
8.9 Pfizer Inc.
8.10 Sanofi Pasteur
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.1 Market Outlook
10.2 Investment Opportunities
Appendix
Related Reports
